Clinical Trial Update: Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial assessing idelalisib for indolent B-cell non-Hodgkin lymphomas completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-09-04